Home Industries Services Case Studies Blogs Custom Research Syndicate Services About Us Contact us
Home Industries Services Case Studies Blogs Custom Research Syndicate Services About Us Contact us

Bleeding Disorders Treatment Market Size by Type (Hemophilia A, Hemophilia B, and Other), By Drug Class (Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, Fibrin Sealants, and Other), Regions, Segmentation, and Projection till 2029

CAGR: 8.9%Current Market Size: USD 15.9 BillionFastest Growing Region: APAC

Largest Market: North AmericaProjection Time: 2022-2029Base Year: 2021

Global Bleeding Disorders Treatment Market- Market Overview:

The Global Bleeding Disorders Treatment market is expected to grow from USD 15.9 billion in 2021 to USD 31.44 billion by 2029, at a CAGR of 8.9%% during the Projection period 2022-2029. The growth of this market is mainly driven owing to the rising population of patients.

Bleeding disorders are characterised by disruptions in the body's normal blood clotting process. Due to the prolonged bleeding, this disease may have catastrophic repercussions in accident situations. There is also a chance that the body will start bleeding on its own. Although some bleeding disorders can also be acquired due to liver diseases, drug interactions, low red blood cell counts, vitamin K deficiencies, and other variables that are covered in detail in the report by geographical tendencies of disease, the majority of bleeding disorders are inherited. The market for treating bleeding disorders is anticipated to grow rapidly due to an increase in the number of people with liver diseases, anaemia, and other blood coagulation issues. Various growth variables are evaluated with dynamics in the study.The market for treating bleeding disorders is expanding due to an increase in the number of patients who have been given the diagnosis, increased research and development efforts, investments from key market players, increased public awareness of bleeding disorders, particularly haemophilia, and successful government initiatives in developed nations to establish a vast network of diagnosis and treatment facilities. But many individuals are unable to access the proper care due to the high cost of pharmaceuticals and a shortage of trained medical professionals, which has been limiting the market's expansion. Treatment market growth is largely constrained by underdeveloped and developing nations, but these nations' markets are also expanding.

Sample Request: - Global Bleeding Disorders Treatment Market

Market Dynamics:

Drivers:                          

  • Increasing occurrence of bleeding disorders and developments in treatments

An increase in the population with bleeding disorders is driving the demand for treatments for these conditions. Over 1,125,000 boys worldwide suffer from a genetic bleeding disorder, of which 418,000 have a mild variety that is frequently undiagnosed. The market for treating bleeding disorders has been expanding as a result of the large number of patients who are receiving therapy in some capacity. In an effort to increase patient understanding of therapy and adoption rates, numerous businesses and academic institutions have been attempting to create new medications and enhance existing ones. The delivery of many replacement drugs has improved, and their potency, immunogenicity, and half-lives have all increased. For the past five years, improvements in bioengineering have benefited in the treatment of disorders that cause bleeding. The bleeding disorders treatment market is likely to increase owing to these advancements during the Projection years.

Restraints:                                             

  • Unfavorable reimbursement situation and high cost for treatment

A significant barrier to the market for treating bleeding disorders is the high cost of care. Hospitalization, lab tests, and routine outpatient checkups are all too expensive. The development of the market for therapies for acquired bleeding disorders is expected to be hampered by other factors, such as a lack of awareness in some developing countries.

Opportunities:

  • Government expenditures on interoperability in healthcare

The federal government's increased investment in encouraging the use of these solutions has a further impact on the market. The market for treating bleeding disorders is also positively impacted by the rise in healthcare spending, improvements in the healthcare infrastructure, and strong demand for extended care delivery.

Challenges                                     

  • Shortage of clinicians

The market for treating bleeding disorders would face substantial obstacles due to the lack of trained professionals and specialists with the necessary skills. Lack of access to effective therapy due to high prescription fees would restrict the market's development rate. The absence of benevolent reimbursement policies will further constrain the growth's potential.

Segmentation Analysis:

The global bleeding disorders treatment market has been segmented based on type, drug class, and regions.

By Type

The type segment is hemophilia A, hemophilia B, and other. The hemophilia A segment led the largest share of the bleeding disorders treatment market with a market share of around 38.3% in 2021. The classification is based on the unique lack of coagulation factor in the patient. Statistics show that haemophilia type A is four times more prevalent than haemophilia type B and is the most common kind. According to data reported in WebMD LLC in 2019, the prevalence of type A varies by country, with 5.4-14.5 cases per 100,000 males being the range. Furthermore, severe haemophilia A, which is associated with severe bleeding symptoms, was present in 50–60% of the population. A lot of the treatments available on the market are also used to treat type A haemophilia.

By Drug Class                                                                                   

The drug class includes recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, fibrin sealants, and other segments. The recombinant coagulation factor concentrates segment led the bleeding disorders treatment market with a market share of around 29.08% in 2021. This rise can be attributed to increasing R&D efforts and pharmaceutical firms' greater focus on recombinant products, which led to the introduction of new drugs. The rising incidence of blood disorders and the expanding popularity of recombinant coagulation factor concentrates are the segment's main growth factors. Recombinant coagulation factor concentrates are used to treat diseases like haemophilia (prevention and control of hemorrhagic episodes).

By Regional Analysis:

The regions analyzed for the bleeding disorders treatment market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North America region dominated the bleeding disorders treatment market and held the 22% share of the market revenue in 2021.

  • North America region witnessed a major share. North America is anticipated to retain a large market position in the blood disease therapeutics market as a result of the rising prevalence of different blood disorders and the rising patient awareness in this field. According to the World Federation of Hemophilia, around 18,000 and 11,000 Americans, respectively, have haemophilia and von Willebrand disease. Additionally, every year 400 neonates with haemophilia A receive a diagnosis, affecting 1 in every 5,000 male births. Two further variables that are significantly aiding regional market expansion are the availability of a robust healthcare infrastructure and rising investments in research and development to discover therapies for blood disorders.
  • Asia Pacific is anticipated to experience significant growth during the predicted period. The region's rising investment in the healthcare sector is anticipated to fuel the market for the treatment of bleeding disorders. Additionally, a sizable patient pool feeds the local market.

Global Bleeding Disorders Treatment Market- Country Analysis:

  • Germany

Germany's Bleeding Disorders Treatment market size was valued at USD 0.604 billion in 2021 and is expected to reach USD 1.125 billion by 2029, at a CAGR of 7.3% from 2022 to 2029.

The emergence of blood illnesses in Germany is driving up need for care for bleeding disorders. The EHC represents about 90,000 individuals with a diagnosis of a rare bleeding disorder such haemophilia, von Willebrand disease (VWD), or another uncommon ailment. Additionally, rising government spending in the healthcare sector fuels the industry.

  • China

China Bleeding Disorders Treatment’s market size was valued at USD 0.508 billion in 2021 and is expected to reach USD 0.859 billion by 2029, at a CAGR of 6.8% from 2022 to 2029. Because more individuals are becoming aware of genetic diseases, the Chinese market is probably going to have a significant revenue share in the market for treating bleeding disorders. The prevalence of bleeding disorders among patients is increasing, and there are medications or therapies available to treat these conditions, which is causing the market to grow. the store Factors like increased R&D activities and pharmaceutical companies' increased focus on developing novel treatments are anticipated to benefit China.

  • India

India's Bleeding Disorders Treatment market size was valued at USD 0.139 billion in 2021 and is expected to reach USD 0.219 billion by 2029, at a CAGR of 5.9% from 2022 to 2029. The region's market is expanding as a result of increasing investments in R&D to find treatments for blood disorders and the presence of a strong healthcare infrastructure.

Key Industry Players Analysis:                                                     

To increase their market position in the global Bleeding Disorders Treatment business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.

  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Prestige Consumer Healthcare Inc.
  • Wellona Pharma
  • Bayer AG
  • Zydus Group
  • Amneal Pharmaceuticals LLC
  • Novartis AG
  • Akorn Operating Company LLC
  • Bausch & Lomb Incorporated
  • Théa Laboratories
  • OASIS Medical
  • Alcon
  • Santen Pharmaceutical Co., Ltd.

Latest Development:

  • In February 2020, Esperoct, an anti-hemophilic factor, was introduced by Novo Nordisk A/S in the United States for the treatment of adults and children with haemophilia A, i.e., to lessen and manage bleeding episodes even after surgery.
  • In November 2020, Pfizer announced the beginning of the marstacimab Phase III BASIS research, an investigational therapy for people with severe haemophilia A or B. It was given fast track designation by the U.S. Food and Drug Administration (FDA) for usage in conjunction with inhibitors as a potential treatment for haemophilia A and B.

Report Metrics

Report Attribute 

Details

Study Period

2021-2029

Base year

2021  

CAGR (%)

8.9%

Market Size

15.9 billion in 2021

Projection period

2022-2029

Projection unit

Value (USD)

Segments covered

By Type, By Drug Class, and Region.

Report Scope

Revenue Projection, competitive landscape, company ranking, growth factors, and trends

Companies covered

Johnson & Johnson Services, Inc., AbbVie Inc., Prestige Consumer Healthcare Inc., Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, Théa Laboratories, OASIS Medical, Alcon, and Santen Pharmaceutical Co., Ltd., among others

By Type

  • Hemophilia A
  • Hemophilia B
  • Others

By Drug Class

  • Recombinant Coagulation Factor Concentrates
  • lasma-derived Coagulation Factor Concentrates
  • Fibrin Sealants
  • Other

Regional scope

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Scope of the Report

Global Bleeding Disorders Treatment Market by Type:

  • Hemophilia A
  • Hemophilia B
  • Other

Global Bleeding Disorders Treatment Market by Drug Class:

  • Recombinant Coagulation Factor Concentrates
  • Plasma-derived Coagulation Factor Concentrates
  • Fibrin Sealants
  • Other

Global Bleeding Disorders Treatment Market by Region:

  • North America
    • USA
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
  • Asia-Pacific
    • Japan
    • China
    • India
    • Korea
    • Southeast Asia
  • South America
    • Brazil
    • Peru
  • Middle East and Africa
    • UAE
    • South Africa
    • Saudi Arabia

Frequently Asked Questions

What will be the market size of the Bleeding Disorders Treatment market?

Global bleeding disorders treatment market is expected to reach USD 31.44 billion by 2029, at a CAGR of 8.9% from 2022 to 2029.

Which region dominate the Bleeding Disorders Treatment market?

North America region dominated the bleeding disorders treatment market and held the 22% share of the market revenue in 2021.

What are the opportunities in Bleeding Disorders Treatment market?

Government expenditures on interoperability in healthcare

What is the key driver of the Bleeding Disorders Treatment market?

Increasing blood-related disorders are primarily driving the growth of the bleeding disorders treatment market.

Which are the leading market players active in the Bleeding Disorders Treatment market?

Leading market players active in the global bleeding disorders treatment market are Johnson & Johnson Services, Inc., AbbVie Inc., Prestige Consumer Healthcare Inc., Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, Th�a Laboratories, OASIS Medical, Alcon, and Santen Pharmaceutical Co., Ltd.